NEW YORK, May 3 (Xinhua) -- U.S.-based pharmaceutical company Pfizer Inc. Tuesday said it raked in 25.66 billion U.S. dollars of revenues in the first quarter this year on strong sales of COVID-19 vaccines and oral antiviral treatment pills, surging by 77 percent year on year.
In particular, COVID-19 vaccines contributed 13.2 billion U.S. dollars of revenues while COVID-19 oral antiviral treatment Paxlovid bagged 1.5 billion U.S. dollars in the quarter.
Meanwhile, Pfizer earned 1.62 U.S. dollars of adjusted diluted earnings per share (EPS) in Q1, growing 72 percent year on year.
It also reaffirmed its expectation of 98 billion to 102 billion U.S. dollars of revenues in 2022, including about 32 billion U.S. dollars from COVID-19 vaccine sales and about 22 billion U.S. dollars of Paxlovid sales.
However, Pfizer revised down yearly guidance of adjusted diluted EPS to 6.25-5.45 U.S. dollars from an earlier guidance of 6.35-6.55 U.S. dollars per share.
The downward adjustment of adjusted diluted EPS in 2022 solely reflected 0.11 U.S. dollar of negative impact for accounting policy change to include all acquired in-process research and development (R&D) expenses, according to a release by Pfizer.
Latest comments